Since the advent of the development of streptomycin in the 1940s, the management and treatment of tuberculosis has been primarily focused on drug interventions. Current discussion into tuberculosis control is dominated by a pharmaceutical rationality, and as such the political economy of the pharmaceutical industry lies behind the \"magic bullet\" approach to tuberculosis control programmes. In this paper the author focuses on the drug rifampicin to explore this in more detail.
Harper, I. What is the relevance of clinical trials findings to national treatment regimens? : the case of rifampicin. (2009) 23 pp.